News & Events zu ENvue Medical Inc (FEED)FEEDENvue Medical Inc

ENvue Medical Begins UroShield Production in the U.S.

ENvue Medical announced that UroShield production has commenced in the United States and that commercial shipments are underway to Peak Medical, the Company's exclusive distributor in the United Kingdom and Republic of Ireland. The Company is fulfilling existing orders under its multi-year distribution agreement with Peak Medical, which, as disclosed in ENvue's August 18, 2026 press release, includes multi-million-dollar minimum purchase commitments through December 2029.

ENvue Medical CEO Emphasizes Profitability Goals and Market Expansion

ENvue Medical issued a letter to shareholders from its CEO Doron Besser, MD, which read in part, "Our objective remains clear: to build a profitable ENvue Medical. I am optimistic about the opportunities ahead of us. We believe that years of investment in our technologies, clinical evidence, hospital relationships, and commercial capabilities have established a strong foundation for the next stage of our development. Our focus now is to translate these investments into broader market adoption, recurring revenue growth, and improved financial performance. While the transition of our common stock from Nasdaq to the OTC market was disappointing for our shareholders and for all of us at ENvue Medical, it has not changed our priorities or our commitment to our technologies, our customers, and the commercial opportunities before us. We continue to evaluate ways to strengthen our capital position and to improve the liquidity of our common stock. We continue to transition ENvue Medical into a leaner, more efficient organization while strengthening the commercial position of our businesses. These priorities are inseparable. Commercial growth provides the revenue needed to achieve profitability, and an efficient operating structure allows that growth to translate into stronger financial performance...As we approach 2027, our priorities are focused on execution: expanding access to the U.S. hospital market, increasing recurring feeding tube revenue, supporting our distribution partners, and operating with financial discipline. For information on our financial results and financial condition, we refer shareholders to our filings with the U.S. Securities and Exchange Commission. We have spent years building the clinical evidence, technology, and commercial relationships behind ENvue Medical. We are now bringing these capabilities together with a leaner operating structure, focused on expanding our commercial reach, increasing recurring revenue, and achieving sustainable profitability. I want to thank our employees in the United States and Israel for their commitment through a demanding year, our partners and clinical customers for their confidence in our technologies, and you, our shareholders, for your continued support."

ENvue Medical's Nasdaq Listing Request Denied

ENvue Medical announced that it has received a decision from the Nasdaq Hearings Panel denying the company's request for continued listing on The Nasdaq Capital Market. As a result, trading of the company's common stock will be suspended and will begin trading on the OTC Markets under the same stock symbol, 'FEED', on September 16.